Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.52 |
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | ACHE | P22303 | 6/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | PAM | P19021 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25955231 | 1.00 | DGKA (0.61) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL21425737 | 0.97 | DGKA (0.61) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL27420396 | 0.94 | DGKA (0.61) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL31399579 | 0.94 | DGKA (0.61) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL26565828 | 0.94 | DGKA (0.61) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL31036510 | 0.94 | DGKA (0.61) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL19032585 | 0.94 | DGKA (0.61) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL31399531 | 0.94 | DGKA (0.61) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL18641884 | 0.94 | DGKA (0.61) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL19032459 | 0.94 | DGKA (0.61) | DGKAPRSS1PRSS2PRSS3NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739652-A1 | LIPIDS AND COMPOSITIONS THEREOF | Kernal Biologics, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260116845-A1 | LIPIDS AND COMPOSITIONS THEREOF | KERNAL BIOLOGICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12215068-B2 | Constrained lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-02-04 | — | — | US | disclosed |
| WO-2025010290-A1 | LIPIDS AND COMPOSITIONS THEREOF | KERNAL BIOLOGICS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| EP-4452925-A1 | NANOMATERIAL COMPRISING DIAMINES | Beam Therapeutics Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-4452928-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240335541-A1 | NANOMATERIALS COMPRISING DIAMINES | BEAM THERAPEUTICS INC. | 2024-10-10 | — | — | US | disclosed |
| US-20240067598-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2024-02-29 | — | — | US | disclosed |
| CN-113039174-B | Ionizable amine lipids | 英特利亚治疗股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| EP-4262817-A1 | NANOMATERIALS COMPRISING ACETALS | Beam Therapeutics Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022140238-A1 | NANOMATERIALS COMPRISING ACETALS | BEAM THERAPEUTICS INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140238-A1 | NANOMATERIALS COMPRISING ACETALS | BEAM THERAPEUTICS INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140252-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | BEAM THERAPEUTICS INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140252-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | BEAM THERAPEUTICS INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| CN-114073677-A | Lipid nanoparticle | 深圳深信生物科技有限公司 | 2022-02-22 | — | — | CN | disclosed |
| US-20220009878-A1 | IONIZABLE AMINE LIPIDS | INTELLIA THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| US-20220009878-A1 | IONIZABLE AMINE LIPIDS | INTELLIA THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| EP-3860972-A1 | IONIZABLE AMINE LIPIDS | Intellia Therapeutics, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020072605-A1 | IONIZABLE AMINE LIPIDS | INTELLIA THERAPEUTICS, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| WO-2020072605-A1 | IONIZABLE AMINE LIPIDS | INTELLIA THERAPEUTICS, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335541-A1 | NANOMATERIALS COMPRISING DIAMINES | PHOSPHO1, SGMS1, AOC1 | DGKA 75/4885PRSS1 4739/4885PRSS2 4853/4885 |
| US-20220009878-A1 | IONIZABLE AMINE LIPIDS | PHOSPHO1, SGMS1, SGMS2 | DGKA 312/4885PRSS1 3614/4885PRSS2 3700/4885 |
| US-12215068-B2 | Constrained lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | DGKA 458/4885PRSS1 1096/4885PRSS2 790/4885 |
| US-20240067598-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | DGKA 458/4885PRSS1 1096/4885PRSS2 790/4885 |
| US-20260116845-A1 | LIPIDS AND COMPOSITIONS THEREOF | LIPC, LIPA, NPC1L1 | DGKA 704/4885PRSS1 3821/4885PRSS2 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.